Annual EBITDA
$19.23 M
+$461.98 M+104.34%
December 31, 2024
Summary
- As of February 22, 2025, BPMC annual EBITDA is $19.23 million, with the most recent change of +$461.98 million (+104.34%) on December 31, 2024.
- During the last 3 years, BPMC annual EBITDA has risen by +$646.93 million (+103.06%).
- BPMC annual EBITDA is now -93.90% below its all-time high of $315.27 million, reached on December 31, 2020.
Performance
BPMC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$27.11 M
+$6.26 M+18.75%
December 31, 2024
Summary
- As of February 22, 2025, BPMC quarterly EBITDA is -$27.11 million, with the most recent change of +$6.26 million (+18.75%) on December 31, 2024.
- Over the past year, BPMC quarterly EBITDA has increased by +$2.36 million (+8.01%).
- BPMC quarterly EBITDA is now -104.27% below its all-time high of $635.01 million, reached on September 30, 2020.
Performance
BPMC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$19.23 M
+$67.21 M+140.10%
December 31, 2024
Summary
- As of February 22, 2025, BPMC TTM EBITDA is $19.23 million, with the most recent change of +$67.21 million (+140.10%) on December 31, 2024.
- Over the past year, BPMC TTM EBITDA has increased by +$151.34 million (+114.56%).
- BPMC TTM EBITDA is now -94.43% below its all-time high of $345.17 million, reached on June 30, 2021.
Performance
BPMC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
BPMC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +104.3% | +8.0% | +114.6% |
| 3 y3 years | +103.1% | +8.0% | +114.6% |
| 5 y5 years | +105.4% | +8.0% | +114.6% |
BPMC EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +103.1% | -124.8% | +91.3% | at high | +102.8% |
| 5 y | 5-year | -93.9% | +103.1% | -104.3% | +91.3% | -94.4% | +102.8% |
| alltime | all time | -93.9% | +103.1% | -104.3% | +91.3% | -94.4% | +102.8% |
Blueprint Medicines EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $19.23 M(-104.3%) | -$27.11 M(-18.8%) | $19.23 M(-140.1%) |
| Sep 2024 | - | -$33.37 M(+13.2%) | -$47.97 M(-63.7%) |
| Jun 2024 | - | -$29.48 M(-127.0%) | -$132.10 M(-39.9%) |
| Mar 2024 | - | $109.20 M(-215.8%) | -$219.91 M(-50.3%) |
| Dec 2023 | -$442.75 M(-14.3%) | -$94.32 M(-19.7%) | -$442.75 M(-9.0%) |
| Sep 2023 | - | -$117.51 M(+0.2%) | -$486.66 M(-0.4%) |
| Jun 2023 | - | -$117.28 M(+3.2%) | -$488.46 M(-7.2%) |
| Mar 2023 | - | -$113.64 M(-17.8%) | -$526.28 M(+2.5%) |
| Dec 2022 | -$516.84 M(-17.7%) | -$138.23 M(+15.9%) | -$513.56 M(-25.1%) |
| Sep 2022 | - | -$119.31 M(-23.1%) | -$685.26 M(+1.0%) |
| Jun 2022 | - | -$155.10 M(+53.7%) | -$678.17 M(+7.6%) |
| Mar 2022 | - | -$100.91 M(-67.4%) | -$629.98 M(+0.4%) |
| Dec 2021 | -$627.70 M(-299.1%) | -$309.94 M(+176.2%) | -$627.70 M(+56.1%) |
| Sep 2021 | - | -$112.21 M(+4.9%) | -$402.05 M(-216.5%) |
| Jun 2021 | - | -$106.92 M(+8.4%) | $345.17 M(+5.0%) |
| Mar 2021 | - | -$98.63 M(+17.0%) | $328.72 M(+4.3%) |
| Dec 2020 | $315.27 M(-188.5%) | -$84.29 M(-113.3%) | $315.26 M(-5.0%) |
| Sep 2020 | - | $635.01 M(-614.7%) | $331.75 M(-183.0%) |
| Jun 2020 | - | -$123.37 M(+10.1%) | -$399.93 M(+5.4%) |
| Mar 2020 | - | -$112.09 M(+65.3%) | -$379.26 M(+6.5%) |
| Dec 2019 | -$356.07 M | -$67.80 M(-29.9%) | -$356.07 M(-5.8%) |
| Sep 2019 | - | -$96.67 M(-5.9%) | -$377.87 M(+7.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | -$102.70 M(+15.5%) | -$352.75 M(+27.8%) |
| Mar 2019 | - | -$88.89 M(-0.8%) | -$275.94 M(+13.7%) |
| Dec 2018 | -$242.78 M(+62.2%) | -$89.61 M(+25.2%) | -$242.78 M(+18.4%) |
| Sep 2018 | - | -$71.55 M(+176.3%) | -$205.12 M(+20.1%) |
| Jun 2018 | - | -$25.89 M(-53.5%) | -$170.83 M(-4.0%) |
| Mar 2018 | - | -$55.74 M(+7.3%) | -$177.90 M(+18.9%) |
| Dec 2017 | -$149.67 M(+112.5%) | -$51.94 M(+39.4%) | -$149.67 M(+26.3%) |
| Sep 2017 | - | -$37.26 M(+13.0%) | -$118.51 M(+21.5%) |
| Jun 2017 | - | -$32.96 M(+19.8%) | -$97.56 M(+17.6%) |
| Mar 2017 | - | -$27.51 M(+32.4%) | -$82.97 M(+17.8%) |
| Dec 2016 | -$70.44 M(+37.8%) | -$20.78 M(+27.3%) | -$70.44 M(+8.8%) |
| Sep 2016 | - | -$16.32 M(-11.2%) | -$64.75 M(+6.7%) |
| Jun 2016 | - | -$18.37 M(+22.6%) | -$60.70 M(+10.5%) |
| Mar 2016 | - | -$14.98 M(-0.7%) | -$54.92 M(+7.4%) |
| Dec 2015 | -$51.13 M(+30.4%) | -$15.08 M(+22.9%) | -$51.13 M(+1.9%) |
| Sep 2015 | - | -$12.27 M(-2.6%) | -$50.16 M(+4.2%) |
| Jun 2015 | - | -$12.60 M(+12.7%) | -$48.13 M(+10.4%) |
| Mar 2015 | - | -$11.18 M(-20.8%) | -$43.59 M(+11.2%) |
| Dec 2014 | -$39.21 M(+93.4%) | -$14.11 M(+37.8%) | -$39.21 M(+56.2%) |
| Sep 2014 | - | -$10.24 M(+27.1%) | -$25.10 M(+68.9%) |
| Jun 2014 | - | -$8.06 M(+18.5%) | -$14.86 M(+118.5%) |
| Mar 2014 | - | -$6.80 M | -$6.80 M |
| Dec 2013 | -$20.27 M | - | - |
FAQ
- What is Blueprint Medicines annual EBITDA?
- What is the all time high annual EBITDA for Blueprint Medicines?
- What is Blueprint Medicines annual EBITDA year-on-year change?
- What is Blueprint Medicines quarterly EBITDA?
- What is the all time high quarterly EBITDA for Blueprint Medicines?
- What is Blueprint Medicines quarterly EBITDA year-on-year change?
- What is Blueprint Medicines TTM EBITDA?
- What is the all time high TTM EBITDA for Blueprint Medicines?
- What is Blueprint Medicines TTM EBITDA year-on-year change?
What is Blueprint Medicines annual EBITDA?
The current annual EBITDA of BPMC is $19.23 M
What is the all time high annual EBITDA for Blueprint Medicines?
Blueprint Medicines all-time high annual EBITDA is $315.27 M
What is Blueprint Medicines annual EBITDA year-on-year change?
Over the past year, BPMC annual EBITDA has changed by +$461.98 M (+104.34%)
What is Blueprint Medicines quarterly EBITDA?
The current quarterly EBITDA of BPMC is -$27.11 M
What is the all time high quarterly EBITDA for Blueprint Medicines?
Blueprint Medicines all-time high quarterly EBITDA is $635.01 M
What is Blueprint Medicines quarterly EBITDA year-on-year change?
Over the past year, BPMC quarterly EBITDA has changed by +$2.36 M (+8.01%)
What is Blueprint Medicines TTM EBITDA?
The current TTM EBITDA of BPMC is $19.23 M
What is the all time high TTM EBITDA for Blueprint Medicines?
Blueprint Medicines all-time high TTM EBITDA is $345.17 M
What is Blueprint Medicines TTM EBITDA year-on-year change?
Over the past year, BPMC TTM EBITDA has changed by +$151.34 M (+114.56%)